An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.

Clicks: 358
ID: 66428
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 59 articles by views in journal of pharmaceutical sciences

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The BioPhorum Development Group is an industry-wide consortium enabling networking and sharing of common practices for the development of biopharmaceuticals. Forced degradation studies (FDSs) are often used in biotherapeutic development to assess criticality of quality attributes and in comparability studies to ensure product manufacturing process consistency. To gain an understanding of current industry approaches for FDS, the BioPhorum Development Group-Forced Degradation Point Share group conducted an intercompany collaboration exercise, which included a benchmarking survey and group discussions around FDS of monoclonal antibodies. The results of this industry collaboration provide insights into the practicalities of these characterization studies and how they are being used to support the product lifecycle from innovation to marketed products. The survey requested feedback on the intended purpose, materials, conditions, number and length of time points used, and analytical techniques carried out to give a complete picture of the range of common industry practices. This article discusses the results of this global benchmarking survey across 12 companies and presents these as a guide to a common approach to FDS across the industry which can be used to guide the design of FDS based on chemistry and manufacturing control product life-cycle and biomolecule needs.
Reference Key
halley2019anjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Halley, Jennifer;Chou, Yite Robert;Cicchino, Crystal;Huang, Min;Sharma, Vikas;Tan, Niclas Chiang;Thakkar, Santosh;Zhou, Liqiang Lisa;Al-Azzam, Wasfi;Cornen, Stephane;Gauden, Magdalena;Gu, Zhenyu;Kar, Sambit;Lazar, Alexandru C;Mehndiratta, Promod;Smith, John;Sosic, Zoran;Weisbach, Paul;Stokes, Elaine S E;
Journal journal of pharmaceutical sciences
Year 2019
DOI
S0022-3549(19)30591-X
URL
Keywords
stability monoclonal antibody(s) physical stability photodegradation igg antibody(s) biopharmaceutical characterization degradation product(s) developability forced conditions

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.